Drugs / STC-15
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05584111 | Nov 2022 → Aug 2024 | cancer | STORM Therapeutics LTD | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06975293 | May 2025 → Dec 2027 expected | dedifferentiated liposarcoma, leiomyosarcoma | STORM Therapeutics LTD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STC-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975293 ↗ |
| Action | Inhibit | “STC-15, a METTL-3 Inhibitor” NCT05584111 ↗ |
| Route | Oral | “STC-15 oral capsules various dosing regimen in 3-week cycles” NCT05584111 ↗ |
| Target | METTL3 | “STC-15, a METTL-3 Inhibitor” NCT05584111 ↗ |